Male contraceptive gel hits Kenyan market

Image result for family planning pills

For decade family planning has bee associated with feminine, however the norm will soon take a new twist following the introduction of new male contraceptive in the market which comes in gel form.

Kenya is among seven countries and nine cities in which a new male contraceptive gel will be tested.

The contraceptive which men will be expected to apply on the upper parts of their arms everyday was deemed key in bringing a balance in bedroom affairs by making men equally responsible in family planning matters.

In a report by Komonews.com, the contraceptive will be a self delivery method deemed to replace use of condoms though it does not guarantee any protection against Sexually Transmitted Infections (STIs).

University of Washington’s School of Medicine, Seattle, has already began enrolling couples for clinical trials of the contraceptive dubbed revolutionary. Stephanie Page, a medicine professor at the university, said on application, the gel would be absorbed through the skin to inhibit men from impregnating their partners.

“The really pioneering thing here is there have been other studies of male hormonal contraceptive products but this is the first self-delivered method. One would be expected to pump the gel once and then spread it on upper sides of the arm for absorption through skin,” Page said.

According to scholars from the institution, the gel comprises segesterone acetate and testosterone designed to reduce men’s sperm production without reducing sexual drive or enjoyment.

According to Page, currently, the responsibility of birth control depends on women more, a trend which needs to be reliably overturned.

Kenya among countries where new male contraceptive will be on trial

 

It is estimated that 85 million pregnancies, about 40% of all pregnancies across the world, were unplanned.

This contraceptive will compliment condom use, withdrawal during sex and vasectomy for men. Over 400 couples are anticipated to enroll in the first test of the gel known as Nestorone or NES/T. T

he trial will be first launched in Seattle, Los Angeles, and Kansas City, Kan, before the test is conducted in Chile, England, Italy, Kenya, Scotland, and Sweden.

 

Leave a Reply

Your email address will not be published. Required fields are marked *